Vertical zonation of the Siberian Arctic benthos: bathymetric boundaries from coastal shoals to deep-sea Central Arctic.

The bathymetric distribution of species of Annelida, Crustacea and Echinodermata from the region including the Kara, Laptev and East Siberian seas and the adjacent region of the deep-sea Central Arctic was analysed. We focused on vertical species ranges revealing zones of crowding of upper and lower species range limits. Using published data and in part the material obtained during the expeditions of the P.P. Shirshov Institute of Oceanology, we evaluated species vertical distribution from 0 m to the maximum depth of the Central Arctic (~4,400 m). The entire depth range was divided into smaller intervals; number of upper and lower limits of species depth ranges was counted and plotted to visualize the range limits crowding. Several zones of crowding of vertical species range limits were found for all analysed macrotaxa. The most significant zones occurred at depths of 450-800 m and 1,800-2,000 m. The first depth zone corresponds to the boundary between the sublittoral and bathyal faunas. The last one marks the boundary between the bathyal and abyssal faunas. Depths of these boundaries differ from those reported from other Ocean regions; possible explanations of these differences are discussed.

Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.

INTRODUCTION: This article presents the results of an international, multicenter, randomized, double-masked, placebo-controlled clinical study of Visomitin (Mitotech LLC, Moscow, Russian Federation) eye drops in patients with dry eye syndrome (DES). Visomitin is the first registered (in Russia) drug with a mitochondria-targeted antioxidant (SkQ1) as the active ingredient. METHODS: In this multicenter (10 sites) study of 240 subjects with DES, study drug (Visomitin or placebo) was self-administered three times daily (TID) for 6 weeks, followed by a 6-week follow-up period. Seven in-office study visits occurred every 2 weeks during both the treatment and follow-up periods. Efficacy measures included Schirmer's test, tear break-up time, fluorescein staining, meniscus height, and visual acuity. Safety measures included adverse events, slit lamp biomicroscopy, tonometry, blood pressure, and heart rate. Tolerability was also evaluated. RESULTS: This clinical study showed the effectiveness of Visomitin eye drops in the treatment of signs and symptoms of DES compared with placebo. The study showed that a 6-week course of TID topical instillation of Visomitin significantly improved the functional state of the cornea; Visomitin increased tear film stability and reduced corneal damage. Significant reduction of dry eye symptoms (such as dryness, burning, grittiness, and blurred vision) was also observed. CONCLUSION: Based on the results of this study, Visomitin is effective and safe for use in eye patients with DES for protection from corneal damage. FUNDING: Mitotech LLC.